ABX196 for Hepatocellular Carcinoma

Phase-Based Progress Estimates
MD Anderson Cancer Center, Houston, TXHepatocellular CarcinomaABX196 - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new drug, ABX196, to see if it is safe and effective in treating hepatocellular carcinoma when used with nivolumab.

Eligible Conditions
  • Hepatocellular Carcinoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Through study completion, an average of 1 year

Month 12
Alpha Fetoprotein Serum concentrations
Month 12
Duration of Response (DOR)
Objective Response Rate (ORR)
Month 24
Progression-Free Survival
Year 1
Incidence of adverse events (AEs)

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

1 Treatment Group

1 of 1

Experimental Treatment

48 Total Participants · 1 Treatment Group

Primary Treatment: ABX196 · No Placebo Group · Phase 1 & 2

Experimental Group · 1 Intervention: ABX196 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year

Who is running the clinical trial?

Abivax S.A.Lead Sponsor
20 Previous Clinical Trials
4,217 Total Patients Enrolled
C3 Research AssociatesUNKNOWN
2 Previous Clinical Trials
111 Total Patients Enrolled
Darren SIGAL, MDPrincipal InvestigatorScripps Clinic/Scripps MD Anderson Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 13 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have never had a condition called hepatic encephalopathy.
You do not have a problem with alcohol or drug abuse.
You have received treatment for liver cancer in the past.
You are eligible to receive nivolumab as a treatment option.

Frequently Asked Questions

Is this investigation unprecedented in its approach?

"Presently, ABX196 is being trialled at two locations across one nation. The inaugural trial for the drug was conducted in 2019 by Abivax S.A., and involved 48 patients who completed both phases of clinical testing successfully. Since then, no further studies have been concluded." - Anonymous Online Contributor

Unverified Answer

What is the current participant count of this clinical experiment?

"Affirmative. According to the clinicaltrials.gov website, this investigation is actively recruiting patients who meet their criteria. This study was first published on August 30th 2019 and has since been modified on March 25th 2021. 48 participants need to be enrolled between two medical sites in order for it to progress further." - Anonymous Online Contributor

Unverified Answer

To what extent has ABX196 been tested in prior research?

"Currently, there is only one active clinical trial researching ABX196 with no Phase 3 trials in effect. Most of the research for this drug is taking place at Houston, Texas though two other sites are also running relevant tests." - Anonymous Online Contributor

Unverified Answer

Are there any opportunities for volunteers to join this research project?

"According to clinicaltrials.gov, this research is seeking participants at the moment; it was initially advertised on August 30th 2019 and recently revisited on March 25 2021." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.